Navigation Links
Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
Date:2/23/2012

SUNNYVALE, Calif., Feb. 23, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, today announced that Gerald E. Commissiong, President and CEO, will present the Company's updated business plan at the 2012 National Investment Banking Association (NIBA) conference on Thursday, February 23, 2012 at 12:25pm CST at Le Pavillon Hotel in New Orleans, LA. Mr. Commissiong will also be holding 1-on-1 meetings with investors.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics and biomarkers surrounding the intellectual property and proprietary technologies it owns and has rights to for the treatment and diagnosis of Parkinson's disease and other human diseases.  The Company owns the intellectual property rights to an anti-apoptotic therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"), and owns an inventory of 88 cell lines referred to as "PhenoGuard Cell Lines" from which MANF was discovered. The Company also has a license to the NuroPro™ diagnostic test for Parkinson's disease from Power3 Medical Products. For further information please visit www.amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications, advantages presented by Amarantus' PhenoGuard technology, and/or possible benefits of the NuroPro™ diagnostic platform, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These f
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
2. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
3. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
4. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) ... trials at its mid-Atlantic late-phase research facility, located ... with the idea of closing patient disparities in ... medical advances," said Continental's CEO, Saleh Stevens ... immortal cell line of Henrietta Lacks, dubious ethical ...
(Date:11/23/2014)... 23, 2014 Apiscent Labs, a ... fine chemical ingredients to the global pharmaceutical and ... its new website, Apiscent.com. , The Apiscent.com homepage ... clean design, easy navigation, rotating images and content ... stand out. , The company’s work ...
(Date:11/22/2014)... November 21, 2014 RURO, Inc., ... provider, has released Limfinity® version 5.1.4. , RURO’s ... of Limfinity® than ever in RURO’s 8 year ... minority framework enhancement. Limfinity® version 5.1.4 is the ... and beyond bug fixes! , Limfinity® 5.1.4 release ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... Champions,Biotechnology, Inc. (OTC Bulletin Board: CSBR), a ... Dr. David,Sidransky, Director of the Head and Neck ... Medicine, to serve as Chairman of the Board,replacing ... since 1991. Dr.,Sidransky was appointed to serve on ...
... to customers in 2006, ALLERCA,s hypoallergenic cats have established a unique ... ... world., WILMINGTON, Calif., Oct. 23 ALLERCA, the company that,developed the ... first kitten deliveries to,eager customers. Since then, the company has delivered dozens ...
... of phase 2 breast cancer data show preferential, ... -- Results from 169 patients treated with adecatumumab ... apparent lack of immunogenicity of the antibody, ... ), a biopharmaceutical company focusing on the development of,novel, proprietary ...
Cached Biology Technology:Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 2Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 3Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 4One Year On, ALLERCA Hypoallergenic Cats Bring 'Sneeze Free' Companionship to Allergy and Asthma Sufferers 2One Year On, ALLERCA Hypoallergenic Cats Bring 'Sneeze Free' Companionship to Allergy and Asthma Sufferers 3Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 2Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 3Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 4Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 5
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... the University of Minnesota will help corn and soybean farmers ... change. The project is funded by a five-year, $4.1 ... of Food and Agriculture (NIFA). The aim is to take ... in anticipation of climatic changes such as stronger storms and ...
... (July 6, 2011) A new animal study from Europe ... their newborn,s kidney development. Among the most significant aspects ... too little salt during pregnancy had an adverse effect on ... such disruption can lead to high blood pressure in later ...
... of the hidden dangers that may be lurking in our ... Europe are redevelopments of land that used to belong to ... can leave highly carcinogenic pollutants in the soil. There are ... and treated across Europe, according to EU estimates. Developers ...
Cached Biology News:U of M project will help corn and soybean farmers prepare for climate change 2A mother's salt intake could be key to prenatal kidney development 2A mother's salt intake could be key to prenatal kidney development 3Dealing with pollution James Bond style 2Dealing with pollution James Bond style 3
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
supplied with 10x reaction buffer...
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
Biology Products: